文献速递神经肿瘤

动脉内NEO100促进检查点抑制性治疗抗体在小鼠脑部恶性肿瘤模型中的脑内递送

Enhanced brain entry of checkpoint-inhibitory therapeutic antibodies facilitated by intraarterial NEO100 in mouse models of brain-localized malignancies.
PubMed 文献 · J Neurosurg · 2023-02-03

研究采用脑内植入胶质母细胞瘤或黑色素瘤细胞的免疫健全小鼠,单次动脉内注射NEO100开放血脑屏障,将鼠源抗PD-1/PD-L1抗体与NEO100共同注射或另行静脉注射,定量抗体脑内渗透和CD8+ T细胞浸润并监测生存。结果显示动脉内NEO100增加检查点抑制性抗体脑内蓄积和T细胞数量,两种肿瘤模型中单次干预实现动物长期生存,而无NEO100时抗体治疗效果远较差。

要点

  • 动脉内NEO100可增加检查点抑制性抗体在小鼠脑内的蓄积并增多T细胞。
  • 两种脑部恶性肿瘤模型中,动脉内NEO100联合抗体单次干预实现动物长期生存。
  • 无NEO100时抗体治疗效果远较差。

核心结论

  • 动脉内NEO100开放血脑屏障促进检查点抑制性抗体进入脑肿瘤并 enabling 其治疗活性,同时增加T细胞募集水平。

研究设计与样本

  • 免疫健全小鼠脑内植入同基因胶质母细胞瘤或黑色素瘤细胞,接受单次动脉内NEO100注射以开放血脑屏障。
  • 一剂鼠源抗PD-1/PD-L1抗体与NEO100共同注射或另行静脉注射,定量抗体脑内渗透和肿瘤微环境CD8+ T细胞浸润水平,并监测动物生存。

主要发现

  • 动脉内NEO100使检查点抑制性抗体在脑内蓄积增加,同时T细胞数量增多。
  • 两种恶性肿瘤模型中,动脉内NEO100联合抗体单次干预导致动物长期生存。
  • 无NEO100时抗体治疗效果远较差。

局限性

  • 原文未报告局限性

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVE: Immune checkpoint-inhibitory therapeutic antibodies have shown striking activity against several types of cancers but are less effective against brain-localized malignancies, in part due to the protective effect of the blood-brain barrier (BBB). The authors hypothesized that intraarterial (IA) delivery of a novel compound, NEO100, has the potential to safely and reversibly open the BBB to enable brain-targeted therapeutic activity of checkpoint-inhibitory antibodies. METHODS: Immunocompetent mice with syngeneic glioblastoma or melanoma cells implanted into their brains were subjected to a single IA injection of NEO100 to open their BBB. One dose of murine anti-PD-1/PD-L1 antibody was either coinjected with NEO100 or separately injected intravenously. Brain penetration of these antibodies and levels of CD8+ T cell infiltrate into the tumor microenvironment were quantitated and animal survival was monitored. RESULTS: IA NEO100 enabled the increased accumulation of checkpoint-inhibitory antibodies in the brain, along with greater numbers of T cells. In both malignancy models, a single intervention of IA NEO100 combined with antibody resulted in the long-term survival of animals. Antibody treatment in the absence of NEO100 was far less effective. CONCLUSIONS: BBB opening by IA NEO100 facilitates brain tumor access by checkpoint-inhibitory antibodies and enables their therapeutic activity, along with increased levels of T-cell recruitment.

来源:J Neurosurg,查看原文。版权归原作者所有。

引用

  1. Wang W, He H, Zeng S, et al. Enhanced brain entry of checkpoint-inhibitory therapeutic antibodies facilitated by intraarterial NEO100 in mouse models of brain-localized malignancies. J Neurosurg. 2023. PMID: 36738464. doi:10.3171/2022.12.JNS221285

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。